Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

Zajicek, 2003, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial, Lancet, 362, 1517, 10.1016/S0140-6736(03)14738-1 Hampson, 1998, Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants, Proc Natl Acad Sci USA, 95, 8268, 10.1073/pnas.95.14.8268 Molina-Holgado, 2002, Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling, J Neurosci, 22, 9742, 10.1523/JNEUROSCI.22-22-09742.2002 Skaper, 1996, The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons, Proc Natl Acad Sci USA, 93, 3984, 10.1073/pnas.93.9.3984 Chang, 2001, Effects of cannabinoids on LPS stimulated inflammatory mediator release from macrophages: involvement of eicosanoids, J Cell Biochem, 81, 715, 10.1002/jcb.1103 Arevalo-Martin, 2003, Therapeutic action of cannabinoids on a murine model of multiple sclerosis, J Neurosci, 23, 2511, 10.1523/JNEUROSCI.23-07-02511.2003 Zajicek, 2005, Cannabinoids in multiple sclerosis (CAMS) study, safety and efficacy data from up to 12-months follow-up, J Neurol Neurosurg Psychiatry, 76, 1664, 10.1136/jnnp.2005.070136 McDonald, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, 50, 121, 10.1002/ana.1032 Smith, 2001, Normalised accurate measurement of longitudinal brain change, J Comput Assist Tomogr, 25, 466, 10.1097/00004728-200105000-00022 Smith, 2002, Accurate, robust and automated longitudinal and cross sectional brain change analysis, Neuroimage, 17, 479, 10.1006/nimg.2002.1040 2001, Randomised controlled trial of interferon-beta-1a in secondary progressive MS: clinical results, Neurology, 56, 1496, 10.1212/WNL.56.11.1496 2011 Hobart, 2009, Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods, Health Technol Assess, 13, 1, 10.3310/hta13120 Fischer, 2001 Cohen, 2001, Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial, Arch Neurol, 58, 961, 10.1001/archneur.58.6.961 Molt, 2011, Longitudinal measurement invariance of the multiple sclerosis walking scale-12, J Neurol Sci, 305, 75, 10.1016/j.jns.2011.03.008 Pinheiro, 2000 Wolinsky, 2007, Glatiramer acetate in primary progressive multiple sclerosis: results from a multinational multicenter double blind placebo controlled trial, Ann Neurol, 61, 14, 10.1002/ana.21079 Novotna, 2011, A randomized double blind placebo-controlled, parallel group, enriched design study of nabiximols (Sativex) as add-on therapy in subjects with refractory spasticity caused by multiple sclerosis, Eur J Neurol, 18, 1122, 10.1111/j.1468-1331.2010.03328.x Zajicek, 2012, Multiple sclerosis and extract of cannabis: results from the MUSEC trial, J Neurol Neurosurg Psychiatry, 83, 1125, 10.1136/jnnp-2012-302468